Extended Data Fig. 1: High throughput screening of FDA-approved drugs that inhibits spike and ACE2 interaction using the SURF reporter in living cells.
From: Fluorogenic reporter enables identification of compounds that inhibit SARS-CoV-2
(a) Schematic showing experimental procedure. (b) Volcano plot of ~1600 drugs in inhibiting the PPI of spike and ACE2. HEK293T cells were transfected with the SURF reporter. SURF fluorescence was normalized by mCherry. Cells were incubated with compounds at 10 𝜇M concentration for 24 h before imaging. The dotted horizontal and vertical red lines represent p-value = 0.01 and 40% PPI inhibition, respectively. P value, two-sided non-paired t-test between compound- and DMSO-treated groups (n = 5). (c) Normalized SURF fluorescence of cells incubated with 15 compounds by a second round of imaging. The dotted red line represents 50% PPI inhibition. Data are mean ± s.d. (n = 5). (d) Inhibition kinetics of the identified drugs against spike and ACE2 interaction. Each clinical drug (10 𝜇M) was added to HEK293T cells expressing the SURF reporter, followed by time-lapse imaging. Estimated PPI half-time (𝜏) upon inhibition is shown for each drug. Data are mean ± s.d. (n = 5).
